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ITGAM was recently found to be associated with systemic lupus erythematosus (SLE) in populations of not
only European ancestry, but also in Hispanic- and African-Americans, Mexicans and Colombians. The risk
alleles in the gene, however, were found to be monomorphic in two Asian populations examined:
Japanese and Korean. In this study, using a collection of 910 SLE patients and 2360 controls from
Chinese living in Hong Kong, analyzed by both genome-wide association and direct sequencing, we con-
firmed the association of the same risk alleles in ITGAM with the disease. These findings were further repli-
cated in the Thai population with 278 patients and 383 ethnicity- and geography-matched controls.
Subphenotype stratification analyses showed significantly more involvement of the gene in patients with
renal nephritis and neurological disorders. Although our results support a pivotal role by rs1143679
(R77H) in disease association, our data also suggests an additional contribution from rs1143683, another
non-synonymous polymorphism in this gene (A858V). Therefore, despite the low-allele frequencies of the
risk alleles of the gene in our two Asian populations, ITGAM was confirmed to be a risk factor related to dis-
ease susceptibility and probably severe manifestations of SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a prototype auto-
immune disease characterized by autoantibody production and
multiple organ damage. Both strong genetic predisposing
factors and environmental effects are involved in the disease,
and there are apparent population differences in terms of
disease prevalence and manifestations (1). Asians have a
higher disease prevalence (100 patients/100 000 for women)
and more renal involvement (2–4) than Caucasians. Population
differences in term of susceptibility genes were also well docu-
mented (5–7). Identifying differences in genetic susceptibility
towards the disease could shed light on the mechanisms of the
disease and have implications on its clinical intervention.
In several recent studies, ITGAM has been found to be
associated with SLE (8–11). In the study of Nath et al.,
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SNP rs1143679, a non-synonymous SNP that converts Argi-
nine 77 to Histidine, showed the most significant association
with the disease in Caucasians and also in two African-
American populations, among many other SNPs in the gene
also with significant association. The study by Nath et al.
found that any haplotype carrying the risk allele at
rs1143679 explained the global haplotype association. In a
recent study by Han et al. (11), the association and the role
of rs1143679 were confirmed in several different ethnicities,
such as Hispanic- and African-Americans, Mexicans and
Colombians, with large number of samples studied.
However, in their study, two Asian populations, the Japanese
and Koreans, with a combination of 907 cases and 594 con-
trols examined, were found to be monomorphic on the SNPs
associated with the disease in other populations.
In this study, we have examined the involvement of ITGAM
in two Asian populations: Chinese living in Hong Kong and
Thai living in Bangkok. This study includes two independent
experimental settings. In a genome-wide association study
(GWAS), we genotyped 314 SLE samples collected in Hong
Kong using Illumina 550K Beadchip and analyzed the data
against 920 control samples. In another setting, by direct
sequencing, we genotyped four SNPs in ITGAM, namely
rs1143679, rs9888739, rs1143683 and rs1143678, in 918
SLE cases and 1440 healthy controls from our Hong Kong col-
lection as well as case–control study samples collected in
Thailand. Our study confirmed the association of the gene
with SLE in these two populations. It also points out some
potential differences between our findings and the reported
results from other ethnicities.
RESULTS
Association of ITGAM with SLE by GWAS
We genotyped 320 SLE samples randomly selected from our
Hong Kong SLE collection by Illunima 550K Beadchip, and
314 of them passed quality control. We analyzed our case
samples against 920 controls, which include 400 healthy indi-
viduals of Chinese ethnicity and 520 samples from two other
studies on schizophrenia and HBV infection in Hong Kong
Chinese. The allele frequencies of the ITGAM SNPs were
found to be very similar in the three different control
groups. In Table 1, we listed the SNPs in and around
ITGAM (within 100 kb up- and down-stream of the gene)
that showed significant association with the disease, together
with rs11574637, the SNP that was found to be associated
with SLE in the study of Hom et al. It can be seen from
Figure 1 that all the five SNPs showed significant association
with SLE in ITGAM have high linkage disequilibrium (LD)
with each other. SNP rs11574637 was not associated with
SLE in our population, a finding different from result reported
by Hom et al. This result probably reflected the LD difference
of rs11574637 with other SNPs in the ITGAM gene between
the two populations (e.g. between rs1143683 and
rs11574637, r2 ¼ 0.8 and 0.65 in Caucasians and Chinese,
respectively, Fig. 1). As speculated by Hom et al. and later
confirmed by two other studies (8–10), the association seen
from rs11574637 is probably due to the LD with the non-
synonymous SNPs in the ITGAM gene.
Using the samples from our Hong Kong SLE collection, we
further genotyped four SNPs that were found to be associated
with SLE in the previous studies as well as from findings from
our own GWAS. SNP rs1143679 was not on the Illumina
550K Beadchip but was found to play a pivotal role in
disease association reported by Nath et al. (10), and was there-
fore included for further study. In both Hong Kong samples
and samples from Thailand, the association of ITGAM with
SLE was confirmed (Table 2). Interestingly, the risk alleles
are much lower in frequency in our populations compared
with other populations, especially for the risk alleles in
Hong Kong Chinese. Of the four SNPs genotyped, only
rs1143683 and rs1143679 showed significant association
with the disease in Hong Kong samples. The Thai samples
showed much higher allele frequencies for these SNPs in the
controls and significant association for all four SNPs geno-
typed. It seems that the risk alleles may have larger effect
sizes in the Thai samples, but testing for heterogeneity of
the ORs between the two populations were not significant.
However, the negative result in the heterogeneity test
between the two populations could be just a reflection of
low power for this analysis.
Involvement of ITGAM towards severe disease
manifestations
Since SLE is an extremely heterogeneous disease, we went on
to ask the question whether the risk alleles in ITGAM are also
associated with different manifestations in our Hong Kong
samples. The risk alleles in the gene seem to show association
only in the patients with renal nephritis but not in patients
without, and comparison between patients with and without
renal nephritis is significant for both rs1143683 and
rs1143679 (P ¼ 0.022 and 0.029, respectively, Table 3).
Similar findings were detected for patients with neurological
disorders, for which significant association were found in
patients positive for the phenotype despite the small sample
size (n ¼ 46), whereas the association is marginally significant
for the phenotype-negative patients (Table 3). For several
other manifestations, the risk SNPs showed higher ORs in
patients positive for the subphenotypes than in patients nega-
tive for them, such as on anti-dsDNA antibody, hematological
disorder and immunological disorder, although patients-only
analysis did not show significant difference. Interestingly,
the risk alleles seem to associate with the disease in patients
negative for photosensitivity. It should be noted that the sig-
nificance in statistics is before correction for multiple
testing, and the subphenotype stratification test is prone to
both false-positive and false-negative results (see Supplemen-
tary Material, Figs S1–S2 for power calculation of this study).
A definitive conclusion for subphenotype association probably
requires a significant increase in sample size and/or replication
work in other Asian collections.
Independently contributing variants to the association
The studies by Nath et al. and Han et al. have demonstrated that
the association on ITGAM gene probably stem from the risk
allele at rs1143679, which converts Arginine 77 to Histidine.
From analyzing the Hong Kong samples by logistic regression
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and conditioning on each single SNP, none of the SNPs geno-
typed showed significant association independent of one
another, probably reflected the low power of the study on rare
alleles. Logistic regression analysis on Thai samples indicates
that rs1143679 remains significant when controlling the effect
of rs9888739 or rs1143678. However, both rs1143679 and
rs1143683 lose significant association when analyzed with
each other in the logistic regression analysis.
Haplotype analysis of the Hong Kong samples showed only
marginal significance in disease association for haplotype
TTAT formed by rs1143679, rs9888739, rs1143683 and
rs1143678 (P ¼ 0.021). Not surprisingly, none of the tests on
an independent contribution from the SNPs in the haplotype
analysis produced significant results. For the Thai samples, for
whom the risk alleles have significantly higher frequencies, hap-
lotype TTAT increased from 1.69% in controls to 6.46% in
cases, and gave a P-value of 3.20  1025 for disease associ-
ation. Independent effect of rs1143679 toward the haplotype
association is significant (P ¼ 0.0074, significant difference
between haplotypes TTAT and CTAT). Surprisingly, indepen-
dent effect test for rs1143683 is also significant in the haplotype
test (P ¼ 0.0061, significant difference between the effect of
haplotypes CCAC and CCGC formed by the four SNPs).
When analyzed conditioning on the effect of rs1143679, there
is also a residual effect of the haplotypes (P ¼ 0.046), indicating
association besides rs1143679.
SNP rs1143683 seems to be the most ancient allele among the
four SNPs with the highest minor allele (risk allele) frequency
among the four SNPs and the D’-values equal to 1 among all
four SNPs. Therefore, in addition to performing statistical analy-
sis, we took away the samples carrying the T allele (the rare, risk
allele) of rs1143679 from the analysis and analyzed the rest of the
samples. For the Hong Kong samples, rs1143683 remains signifi-
cantly associated with the disease (OR: 1.63, 95% CI: 1.00–2.65,
P ¼ 0.046). For the Thai samples, rs1143683 has an OR of 1.70
when the remaining samples were analyzed, but the effect failed
to show significance (P ¼ 0.14), presumably due to the small
sample size. Altogether, these results seem to indicate that, in
addition to supporting an independent contribution from
rs1143679, other variants, probably rs1143683, may have inde-
pendent effect of its own.
DISCUSSION
The risk allele of rs1143679 (T) has a frequency of 9–11% in
European-, Hispanic- and African-Americans and the Gullah
population, as well as Mexicans and Colombians, and
showed significant association with SLE in all the tested
populations (10,11). However, in Japanese and Korean
populations, the risk SNP was found to be monomorphic. In
the study with Hong Kong Chinese and the Thai populations,
we confirmed existence of the risk alleles in our populations
and their association with the disease, thus filling the last
missing piece on the picture of the association of the gene
across different ethnicities.
We found that both rs1143863 and rs1143679 reached sig-
nificance in the allelic association test in Hong Kong samples
(P ¼ 0.0037 and 0.021, respectively, Table 2), despite low-
allele frequencies and low power of the study on rare SNPs.
The GWAS data showed slightly higher effect size (OR)
than the replication study (Tables 1 and 2), which may have
reflected a sample selection bias since 74% of the patients
are positive for renal nephritis for the GWAS samples, com-
paring with only 47% in the overall (replication) samples
(included the SLE samples in the GWAS). Interestingly, the
allele frequencies for these SNPs are considerably higher in
the Thai samples, although still much lower than those in
the Caucasians (Table 2). The Thai samples also showed
higher ORs on all the tested SNPs than the Hong Kong
samples (Table 2).
In both Hong Kong and Thai populations, rs1143679 has an
intermediate LD with the other three SNPs genotyped (Fig. 1,
r2 ¼ 0.4–0.6), allowing testing of its independent effect on the
disease association. Although our data support a vital role for
rs1143679, it seems that rs1143683, which converts alanine at
position 858 of the protein to valine, may have further contri-
bution toward disease association. On top of all the statistical
analysis, we observed significant disease association from
rs1143683 after excluding all the samples carrying the risk
allele of rs1143679, supporting independent contribution
besides rs1143679. The relative lower LD between
rs1143679 and other disease-associated variants in our popu-
lations (Fig. 1) is probably the explanation for the different
findings from other populations and from our two Asian popu-
lations. It is also possible that there could be a population
difference in the effect of rs1143683. The low-allele frequen-
cies for these variants in our populations reduce the power of
our study, and it will be important to have other studies reex-
amine the issue of independent contribution of these SNPs.
It seems that in our Hong Kong samples, the association is
tightly related to lupus nephritis (Table 3). The risk alleles also
seem to be associated with some other severe manifestations
of the disease. The confirmation of the ITGAM gene with
Table 1. SNPs in the ITGAM locus showed association with SLE in GWAS
SNP Minor allele MAF (SLE) MAF (control) P-value OR L95 U95
rs9937837 31206440 G 0.043 0.021 0.00077 2.09 1.35 3.24
rs9888739 31220754 T 0.038 0.018 0.00085 2.17 1.36 3.46
rs1143683 31244389 T 0.040 0.019 0.00064 2.18 1.38 3.44
rs7193268 31248498 T 0.040 0.019 0.00064 2.18 1.38 3.44
rs1143678 31250506 T 0.040 0.019 0.00064 2.18 1.38 3.44
rs11574637a 31276375 C 0.016 0.015 0.84 1.07 0.55 2.10
MAF, minor allele frequency.
aSNP rs11574637 was included since it was a SNP previously found to be associated in Caucasians in the study of Hom et al. (9).
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SLE susceptibility in our two Asian populations seems
convincing and consistent with previous reports from other
ethnicities (8–11). However, proving connection of the
genetic variants in this gene with different manifestations
will need much increased sample size and replications from
other collections. Elucidating connections between genetic
Figure 1. LD comparison between Hong Kong Chinese, Thai and Caucasians. (A) Structure of the ITGAM gene from NCBI MapViewer (Build 36.3) and the
position of relevant SNPs in this genomic region. (B) Analysis of LD for the relevant SNPs in this locus for different populations. These include: Hong Kong
Chinese genotyped by Sequencing (Sequen_HK) and Illumina Beadchip (Illumkna550K), Thai samples genotyped by sequencing (Sequen_Thai) and HapMap
Caucasians data (HapMap_Cau). Colour scheme is according to Haploview r2 scheme with darker colour representing better r2-value. Numbers in each cell stand
for pairwise r2-values and an empty cell means pairwise r2 equals to 1 between the corresponding SNPs.
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variations and clinical manifestations, especially severe,
potentially life-threatening ones, will play crucial role in our
understanding of disease mechanisms and improving clinical
intervention. To reach this goal, meta-analysis from different
studies is important, since it will be difficult for a single
study to have the sample size needed to reach a definitive
answer in stratification analysis, especially for genetic variants
of low-allele frequencies.
The product of ITGAM, integrin-aM (CD11bþ), is a mol-
ecule that combines with integrin-b2 to form a leukocyte-
specific integrin. The aMb2-integrin is important in the
adherence of neutrophils and monocytes to stimulated endo-
thelium and in the phagocytosis of complement-coated par-
ticles. Ligation of the complement C3 activation product
iC3b to integrin-aM on antigen-presenting cells results in the
production of TGFb2 and IL10, a process that is essential
for the induction of tolerance (12). Molad et al. (13) reported
that neutrophils from SLE patients with more active disease
expressed greater CD11b/CD18 than those from controls or
patients with less active disease. In addition to clearance of
immune complexes, ITGAM may suppress differentiation of
helper T-cell type 17 (Th17), a pathway that has been
shown to be involved in autoimmunity (14,15). ITGAM
deficiency may also lead to enhanced IL6 production by
antigen presenting cells, which subsequently promotes prefer-
ential differentiation of naı¨ve T cells to Th17 (16).
Despite of the across population association of the gene
with SLE susceptibility, further work is needed to understand
how exactly the risk alleles affect the disease. Another ques-
tion is whether two other non-synonymous polymorphisms,
A858V coded by rs1143683 and P1146S coded by
rs1143678, also play any role in the disease in addition to
R77H coded by SNP re1143679, as statistical analysis is
often incapable of distinguishing the effect of different var-
iants when they have high LD with each other, and much
increased sample sizes are needed to tell them apart. It
seems that P1146 is at a position even better conserved than
R77 in the protein in evolutionary courses (Supplementary
Material, Fig. S3). Functional studies and applying the
knowledge so obtained in clinical interventions are important
steps to be taken following genetic findings.
MATERIALS AND METHODS
The Hong Kong SLE patients were recruited from three Hong
Kong hospitals: Queen Mary Hospital, Tuen Mun Hospital and
Pamela Youde Nethersole Eastern Hospital. Medical records
were reviewed to confirm that subjects met the criteria of
the American College of Rheumatology for SLE diagnosis.
The patients are all self-reported Chinese ethnicity living in
Hong Kong. These included 836 females and 74 males with
a mean age of 44.6 years. The study was approved by the Insti-
tutional Review Board of the University of Hong Kong and
Hospital Authority, Hong Kong West Cluster, New Territory
West Cluster and Hong Kong East Cluster, and all patients
gave informed consent. Clinical and serological data and auto-
antibody profile were recorded at the time of diagnoses. Renal
involvement was defined by proteinuria .0.5 gm/day or
biopsy-proven lupus nephritis. Hematological disorders
included leukopenia, lymphopenia, thrombocytopenia and/or
hemolytic anemia. Neurological disorders included psychosis,
depression, seizure, aseptic meningitis, cognitive dysfunction
and organic brain syndrome. A total of 1440 Hong Kong
Chinese blood donors from Hong Kong Red Cross were
recruited as controls. These included 519 females and 918
males with a mean age of 29.6 years. They are also self-
reported to be of Chinese ethnicity.
Two hundred and seventy-eight Thai patients with SLE
(female:male ratio ¼ 260:18; mean age: 35.6 years) attending
King Chulalongkorn Memorial Hospital, a tertiary referral
center in Bangkok, who fulfilled at least four of the American
College of Rheumatology 1982 revised criteria for SLE, were
included in this study. Three hundred and eighty-three Thai
normal control subjects (female:male ratio ¼ 331:52; mean
age:35.8years) were recruited from unrelated voluntary
healthy donors from the same ethnic background and
geographic area. The study was approved by the Ethics
Table 2. Replication of SLE association by Sequencing in the Hong Kong and Thai collections
SNP rs1143679 rs9888739 rs1143683 rs1143678
SNP position Exon 3 (R77H) Intron 14 Exon 21 (A858V) Exon 30 (P1146S)
Minor alleles T T A T
Hong Kong Control MAF, (%) 0.51 1.4 1.72 1.47
SLE MAF (%) 1.13 2.14 3.05 2.2
OR (95% CI) 2.21 (1.11–4.42) 1.54 (0.97–2.44) 1.79 (1.20–2.67) 1.51 (0.96–2.37)
P-value 0.021 0.063 0.0037 0.073
Thai Control MAF, (%) 2.10 3.41 4.61 3.29
SLE MAF (%) 6.22 8.33 10.31 8.81
OR (95% CI) 3.10 (1.61–5.98) 2.58 (1.49–4.44) 2.38 (1.47–3.84) 2.84 (1.65–4.90)
P-value 4.1  1024 4.4  1024 2.7  1024 9.4  1025
Joint Joint OR (95% CI) 2.82 (1.74–4.59) 1.91 (1.35–2.71) 1.82 (1.33–2.50) 1.95 (1.38–2.75)
Joint P-value 1.25  1025 2.30  1024 1.70  1024 1.07  1024
Heterogeneity P 0.49 0.16 0.25 0.08
Caucasians Control MAF (%) 10.0 12.7 15.2 16.8
SLE MAF (%) 17.0 18.9 23.1 21.4
P-value 1.7  10217 1.61  10223 6.03  1028 8.5  10214
OR (95% CI) 1.78 (1.56–2.03) (10) 1.62 (1.47–1.78) (8) 1.67 (1.39–2.01) (10) 1.40 (1.28–1.53) (8)
MAF, minor allele frequency.
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Table 3. Association of ITGAM SNPs with SLE analyzed by subphenotypes stratification
Subphenotype Comparison rs1143679 OR (95% CI),
P-value
rs1143683 OR (95% CI),
P-value
rs1143678 OR (95% CI),
P-value
Renal involvement SLE (þ) (n ¼ 343) versus control
(n ¼ 1440)
3.61 (1.63–7.98), P ¼ 0.00073 2.42 (1.51–3.89), P ¼ 0.00017 1.95 (1.10–3.47), P ¼ 0.02
SLE (2) (n ¼ 392) versus control
(n ¼ 1440)
1.08 (0.35–3.28), P ¼ 0.90 1.18 (0.67–2.08), P ¼ 0.57 1.22 (0.65–2.30), P ¼ 0.53
Heterogeneity test of OR P ¼ 0.076 P ¼ 0.055 P ¼ 0.28
SLE (þ) (n ¼ 343) versus SLE
(2) (n ¼ 392)
3.35 (1.06–10.58), P ¼ 0.029 2.05 (1.10–3.85), P ¼ 0.022 1.60 (0.77–3.31), P ¼ 0.21
Anti-dsDNA ab SLE (þ) (n ¼ 515) versus control
(n ¼ 1440)
2.56 (1.18–5.56), P ¼ 0.014 1.81 (1.15–2.84), P ¼ 0.0094 1.57 (0.92–2.67), P ¼ 0.096
SLE (2) (n ¼ 220) versus control
(n ¼ 1440)
1.44 (0.41–5.04), P ¼ 0.56 1.59 (0.84–3.00), P ¼ 0.15 1.52 (0.73–3.15), P ¼ 0.26
Heterogeneity test of OR P ¼ 0.44 P ¼ 0.75 P ¼ 0.94
SLE (þ) (n ¼ 515) versus SLE
(2) (n ¼ 220)
1.78 (0.50–6.36), P ¼ 0.37 1.14 (0.58–2.25), P ¼ 0.70 1.04 (0.47–2.29), P ¼ 0.93
Arthritis SLE (þ)(n ¼ 360) versus control
(n ¼ 1440)
1.73 (0.66–4.52), P ¼ 0.26 1.43 (0.83–2.46), P ¼ 0.20 1.62 (0.90–2.91), P ¼ 0.10
SLE (2) (n ¼ 375) versus
control(n ¼ 1440)
2.73 (1.18–6.33), P ¼ 0.015 2.07 (1.27–3.36), P ¼ 0.003 1.48 (0.80–2.74), P ¼ 0.21
Heterogeneity test of OR P ¼ 0.48 P ¼ 0.32 P ¼ 0.84
SLE (þ) (n ¼ 360) versus SLE
(2) (n ¼ 375)
0.63 (0.22–1.79), P ¼ 0.39 0.69 (0.37–1.28), P ¼ 0.24 1.09 (0.53–2.25), P ¼ 0.81
Onset_age SLE (,27) (n ¼ 339) versus
control (n ¼ 1440)
1.91 (0.73–5.00), P ¼ 0.18 1.83 (1.10–3.07), P ¼ 0.019 1.57 (0.84–2.90), P ¼ 0.15
SLE (27) (n ¼ 396) versus
control (n ¼ 1440)
2.48 (1.07–5.75), P ¼ 0.029 1.66 (1.00–2.76), P ¼ 0.048 1.54 (0.86–2.77), P ¼ 0.15
Heterogeneity test of OR P ¼ 0.69 P ¼ 0.79 P ¼ 0.97
SLE (,27) versus SLE (27) 0.77 (0.27–2.18), P ¼ 0.62 1.11 (0.60–2.03), P ¼ 0.75 1.02 (0.49–2.10), P ¼ 0.96
Malar rash SLE (þ)(n ¼ 329) versus control
(n ¼ 1440)
3.23 (1.43–7.30), P ¼ 0.003 1.78 (1.05–3.00), P ¼ 0.03 2.04 (1.16–3.60), P ¼ 0.011
SLE (2) (n ¼ 406) versus control
(n ¼ 1440)
1.36 (0.49–3.80), P ¼ 0.55 1.71 (1.04–2.81), P ¼ 0.033 1.14 (0.60–2.19), P ¼ 0.69
Heterogeneity test of OR P ¼ 0.19 P¼0.91 P ¼ 0.18
SLE (þ) (n ¼ 329) versus SLE
(2) (n ¼ 406)
2.37 (0.81–6.97), P ¼ 0.11 1.04 (0.57–1.92), P ¼ 0.90 1.79 (0.86–3.75), P ¼ 0.12
Anti-Ro ab SLE (þ) (n ¼ 328) versus control
(n ¼ 1440)
2.29 (0.92–5.71), P ¼ 0.066 1.80 (1.07–3.05), P ¼ 0.026 1.96 (1.10–3.48), P ¼ 0.020
SLE (2) (n ¼ 407) versus control
(n ¼ 1440)
2.15 (0.90–5.15), P ¼ 0.08 1.69 (1.02–2.78), P ¼ 0.037 1.22 (0.65–2.30), P ¼ 0.54
Heterogeneity test of OR P ¼ 0.92 P ¼ 0.86 P ¼ 0.28
SLE (þ) (n ¼ 328) versus SLE
(2) (n ¼ 407)
1.07 (0.38–2.96), P ¼ 0.90 1.07 (0.58–1.96), P ¼ 0.83 1.60 (0.77–3.33), P ¼ 0.20
Hematological
disorder
SLE (þ) (n ¼ 364) versus control
(n ¼ 1440)
2.73 (1.17–6.33), P ¼ 0.015 1.83 (1.10–3.04), P ¼ 0.018 1.92 (1.09–3.37), P ¼ 0.021
SLE (2) (n ¼ 371) versus control
(n ¼ 1440)
1.73 (0.66–4.52) P ¼ 0.26 1.65 (0.99–2.77), P ¼ 0.053 1.21 (0.63–2.31) P ¼ 0.57
Heterogeneity test of OR P ¼ 0.61 P ¼ 0.87 P ¼ 0.28
SLE (þ) (n ¼ 364) versus SLE
(2) (n ¼ 371)
1.39 (0.50–3.85), P ¼ 0.53 1.06 (0.58–1.95), P ¼ 0.85 1.60 (0.77–3.31), P ¼ 0.21
Immunological
disorder
SLE (þ) (n ¼ 469) versus control
(n ¼ 1440)
2.79 (1.28–6.05), P ¼ 0.007 1.97 (1.25–3.10), P ¼ 0.003 1.79 (1.06–3.03), P ¼ 0.03
SLE (2) (n ¼ 266) versus control
(n ¼ 1440)
1.22 (0.35–4.26), P ¼ 0.76 1.34 (0.71–2.53), P ¼ 0.37 1.14 (0.53–2.45), P ¼ 0.74
Heterogeneity test of OR P ¼ 0.26 P ¼ 0.33 P ¼ 0.34
SLE (þ) (n ¼ 469) versus SLE
(2)(n ¼ 266)
2.29 (0.64–8.15), P ¼ 0.19 1.47 (0.75–2.89), P ¼ 0.26 1.57 (0.69–3.55), P ¼ 0.28
Neurological disorder SLE (þ) (n ¼ 46) versus control
(n ¼ 1440)
4.73 (1.06–21.13), P ¼ 0.025 4.05 (1.69–9.72), P ¼ 0.0007 4.24 (1.63–11.03),
P ¼ 0.0013
SLE (2) (n ¼ 689) versus control
(n ¼ 1440)
2.05 (0.96–4.37), P ¼ 0.06 1.59 (1.04–2.45), P ¼ 0.032 1.38 (0.83–2.28), P ¼ 0.21
Heterogeneity test of OR P ¼ 0.31 P ¼ 0.051 P ¼ 0.032
SLE (þ) (n ¼ 46) versus SLE
(2)(n ¼ 689)
2.31 (0.51–10.39), P ¼ 0.26 2.54 (1.04–6.21), P ¼ 0.034 3.08 (1.15–8.25), P ¼ 0.019
Continued
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Committee of the King Chulalongkorn University and the sub-
jects all gave informed consent (17).
GWAS
Samples were genotyped by Illumina 550K Human Beadchip.
Initial phase of quality control of the chip data includes geno-
type call rate (.95%), minor allele frequencies (.1%),
Hardy–Weinberg equilibrium test (P . 0.05), relationship
test among individuals and all analyses were performed by
Plink (18). Hidden population structure was examined by
Eigenstrat (19).
Replication
Four of the ITGAM SNPs were genotyped in the replication
phase by direct sequencing of the PCR products. Primer
sequences: SNP rs1143683: forward: TGACTGTGAGAAAT-
GATGGTGAGGA and reverse: CCAGGAGTTCTGACCT
CTGAGTTTTC. SNP rs1143679: forward: AGTGCGACTA
CAGCACAGGCTCAT and reverse: GAGACAAGGAGGTC
TGACGGTGAA. SNP rs9888739: forward: TCACTCCTA
AATTTCCCTAAAAATATGGA and reverse: GAAAGAAC
CATGAGCATGAGCTATTT. SNP rs1143678: forward: TG
TCGCTCTCACTGCCCTCCTCT and reverse: CTACGTG
TGGTCTGGGCAGAGTC. PCR condition used is as
Table 3. Continued
Subphenotype Comparison rs1143679 OR (95% CI),
P-value
rs1143683 OR (95% CI),
P-value
rs1143678 OR (95% CI),
P-value
Oral ulcer SLE (þ) (n ¼ 95) versus control
(n ¼ 1440)
2.42 (0.55–10.75), P ¼ 0.23 0.66 (0.16–2.73), P ¼ 0.56 0.84 (0.20–3.49), P ¼ 0.81
SLE (2) (n ¼ 640) versus control
(n ¼ 1440)
2.19 (1.03–4.67), P ¼ 0.038 1.89 (1.28–2.87), P ¼ 0.0023 1.65 (1.02–2.69), P ¼ 0.041
Heterogeneity test of OR P ¼ 0.9 P ¼ 0.15 P ¼ 0.37
SLE (þ) (n ¼ 95) versus SLE
(2) (n ¼ 640)
1.11 (0.25–4.95), P ¼ 0.89 0.35 (0.08–1.45), P ¼ 0.13 0.51 (0.12–2.15), P ¼ 0.35
Photosensitivity SLE (þ) (n ¼ 151) versus control
(n ¼ 1440)
0.70 (0.09–5.38), P ¼ 0.73 0.77 (0.28–2.16), P ¼ 0.62 0.98 (0.35–2.77), P ¼ 0.98
SLE (2) (n ¼ 584) versus control
(n ¼ 1440)
2.62 (1.24–5.51), P ¼ 0.0085 1.99 (1.31–3.05), P ¼ 0.0011 1.70 (1.03–2.81), P ¼ 0.034
Heterogeneity test of OR P ¼ 0.21 P ¼ 0.086 P ¼ 0.35
SLE (þ) (n ¼ 151) versus SLE
(2) (n ¼ 584)
0.27 (0.04–2.06), P ¼ 0.17 0.39 (0.14–1.10), P ¼ 0.064 0.58 (0.2–1.67), P ¼ 0.31
RNP SLE (þ) (n ¼ 142) versus control
(n ¼ 1440)
3.80 (1.36–10.63), P ¼ 0.0063 1.67 (0.78–3.56), P ¼ 0.18 2.13 (0.98–4.59), P ¼ 0.05
SLE (2) (n ¼ 593) versus control
(n ¼ 1440)
1.83 (0.81–4.14), P ¼ 0.14 1.76 (1.14–2.72), P ¼ 0.010 1.41 (0.84–2.39), P ¼ 0.19
Heterogeneity test of OR P ¼ 0.27 P ¼ 0.91 P ¼ 0.39
SLE (þ) (n ¼ 142) versus SLE
(2) (n ¼ 593)
2.07 (0.70–6.11), P ¼ 0.18 0.95 (0.44–2.08), P ¼ 0.90 1.50 (0.66–3.42), P ¼ 0.33
Serositis SLE (þ) (n ¼ 72) versus control
(n ¼ 1440)
4.73 (1.34–16.66), P ¼ 0.0078 2.55 (1.07–6.05), P ¼ 0.03 2.20 (0.77–6.23), P ¼ 0.13
SLE (2) (n ¼ 663) versus control
(n ¼ 1440)
1.96 (0.90–4.24), P ¼ 0.083 1.67 (1.08–2.54), P ¼ 0.02 1.49 (0.90–2.45), P ¼ 0.12
Heterogeneity test of OR P ¼ 0.33 P ¼ 0.38 P ¼ 0.5
SLE (þ) (n ¼ 72) versus SLE
(2) (n ¼ 663)
2.42 (0.67–8.67), P ¼ 0.16 1.54 (0.64–3.72), P ¼ 0.33 1.48 (0.51–4.31), P ¼ 0.47
Discoid rash SLE (þ) (n ¼ 81) versus control
(n ¼ 1440)
3.9 (1.11–13.72), P ¼ 0.022 2.13 (0.90–5.05), P ¼ 0.078 1.83 (0.65–5.20), P ¼ 0.25
SLE (2) (n ¼ 654) versus control
(n ¼ 1440)
2.00 (0.92–4.34), P ¼ 0.073 1.69 (1.1–2.59), P ¼ 0.015 1.52 (0.92–2.50), P ¼ 0.10
Heterogeneity test of OR P ¼ 0.36 P ¼ 0.63 P ¼ 0.75
SLE (þ) (n ¼ 81) versus SLE
(2) (n ¼ 654)
1.95 (0.54–6.99), P ¼ 0.30 1.26 (0.52–3.04), P ¼ 0.60 1.21 (0.42–3.52), P ¼ 0.73
Anti-sm autoantibody SLE (þ) (n ¼ 65) versus control
(n ¼ 1440)
3.23 (0.73–14.37), P ¼ 0.103 1.76 (0.62–4.94), P ¼ 0.28 1.69 (0.51–5.53), P ¼ 0.38
SLE (2) (n ¼ 670) versus control
(n ¼ 1440)
2.11 (0.99–4.51), P ¼ 0.048 1.74 (1.14–2.65), P ¼ 0.0094 1.54 (0.94–2.52), P ¼ 0.084
Heterogeneity test of OR P ¼ 0.62 P ¼ 0.99 P ¼ 0.89
SLE (þ) (n ¼ 65) versus SLE
(2) (n ¼ 670)
1.53 (0.34–6.85), P ¼ 0.58 1.01 (0.35–2.87), P ¼ 0.99 1.10 (0.33–3.67), P ¼ 0.88
Anti-La autoantibody SLE (þ) (n ¼ 94) versus control
(n ¼ 1440)
1.13 (0.15–8.67), P ¼ 0.90 1.25 (0.45–3.51), P ¼ 0.67 1.59 (0.56–4.51), P ¼ 0.38
SLE (2) (n ¼ 641) versus control
(n ¼ 1440)
2.38 (1.13–5.01), P ¼ 0.019 1.81 (1.19–2.77), P ¼ 0.0052 1.55 (0.94–2.55), P ¼ 0.084
Heterogeneity test of OR P ¼ 0.5 P ¼ 0.51 P ¼ 0.96
SLE (þ) (n ¼ 94) versus SLE
(2) (n ¼ 641)
0.48 (0.06–3.64), P ¼ 0.46 0.69 (0.24–1.96), P ¼ 0.49 1.03 (0.36–2.99), P ¼ 0.96
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follows: 968C, 5 min; 968C, 30 s; 588C, 50 s; 728C, 1 min; for
40 cycles: 728C, 10 min.
Statistical analysis
All SNPs were tested for significant deviation from Hardy–
Weinberg equilibrium in controls and all passed the test
with P-values . 0.05. The SNPs were analyzed for an associ-
ation with the disease by means of comparison of the minor
allele frequency in patients and controls (basic allelic test)
as well as other tests using Plink (18). LD patterns were ana-
lyzed and displayed by HaploView (20). Association of the
SNPs with disease risk was also corrected by logistic
regression using age and sex as covariates and the associations
found in this study remain significant after all the corrections.
Average ORs and P-values jointly analyzed from both the
Hong Kong Chinese and the Thai populations were obtained
by CMH test of association conditional on SNP differences
between the two populations. Potential heterogeneity of ORs
for a given SNP between the two populations was tested
both by Breslow–Day test and by partitioning the x2 statistic
between the two populations. Test of independent contribution
of a SNP controlling for the effect of other SNPs in the same
gene was done by logistic regression as well as haplotype ana-
lyses. Association with subphenotype was analyzed by com-
paring cases with a certain subphenotype with controls,
cases without the subphenotype with controls, heterogeneity
test of two ORs so derived and direct comparison of the
cases with and without the subphenotypes.
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